ASH 2014: Gilead announces good response rates for Zydelig in non-Hodgkin lymphoma

US biotech major Gilead Sciences (Nasdaq: GILD) has announced long-term follow-up results from the registration studies for Zydelig (idelalisib) in relapsed patients with chronic lymphocytic leukemia (CLL) and two types of indolent non-Hodgkin lymphoma (iNHL).

The findings which further describe the duration of response, progression-free survival (PFS) and safety profile of Zydelig are being presented this week at the Annual Meeting of the American Society of Hematology (ASH).

Norbert Bischofberger, executive vice President, R&D and chief scientific officer, Gilead Sciences, said: “The results presented this week demonstrate the long-term benefit of Zydelig in patient populations that often have limited or no treatment options due to age or lack of response to existing therapies. As part of our ongoing effort to further define the safety and efficacy profile of Zydelig, we are continuing to pursue long-term follow-up studies and larger Phase II and Phase III clinical trials in combination with existing treatment regimens in both relapsed and first-line CLL and iNHL.”